Streptococcal Infections Clinical Trial
Official title:
Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract
Group A streptococcus (GAS) causes a variety of human infections. It is also an uncommon but
serious cause of postpartum infections. In contrast to group B streptococcus (GBS)
infection, which causes illness and death in newborns disproportionately more often than it
does in mothers, perinatal GAS infection primarily affects mothers . Invasive GAS infection
is defined by the isolation of GAS from a normally sterile site (e.g., blood) or by the
isolation of GAS from a nonsterile site in the presence of the streptococcal toxic shock
syndrome or necrotizing fasciitis. A postpartum case of invasive GAS is defined as isolation
of GAS during the postpartum period, in association with a clinical postpartum infection
(e.g., endometritis) or from either a sterile site or a wound infection.
Because of the burden and severity of invasive GAS infection, the Centers for Disease
Control and Prevention (CDC) hosted a meeting in to formulate guidelines for responding to
postpartum and postsurgical GAS infections. However, we could not find any recommendations
for long-term follow-up of patients who had GAS infection subsequent to delivery or
gynaecological procedures, or further recommendations regarding subsequent delivery or
gynaecological invasive procedures. It is possible that women who had GAS as a cause of
vaginal infection may have a tendency to be carriers of this organism, but this has never
been proven. We believe it is of importance to determine if women who have had one infection
may be long-term carriers which may pose a risk during future pregnancies.
The objective of the present study is to evaluate the incidence of long term gynaecological
carrier state of patients who had GAS invasive infection following delivery, and to provide
guidelines for follow-up and treatment of such patients.
The proposed study may answer the question whether this endogenous GAS origin represents
chronic GAS carrier state, similar to the known GBS carrier state. As some of these patients
had severe infections (sometimes life threatening) a protocol for long-term follow up and
management is necessary in case an invasive procedure is done (IUD insertion, endometrial
biopsy, curettage or delivery) in order to prevent recurrent infection. The information
collected in the study will enable us to afford recommendations for follow up and
prophylaxis in the future.
Research plan The study population will include patients diagnosed with GAS invasive
infection following delivery or gynaecological procedures (such as endometrial biopsy, D&C
or IUD insertion) at Hadassah university hospitals, and patients in whom an isolation of GAS
from the vagina without infection was reported. The study will consist of two parts,
prospective and retrospective.
1. Retrospective study
1. The records of all patients diagnosed with GAS infection/isolation in the past 3
years (2003-2005) will be reviewed. The estimated occurrence of GAS isolation from
the genital tract in Hadassah hospital is 15 cases every year (Moses personal
communication).
2. Patients' files will be reviewed for demographic and clinical variables associated
with the development of GAS infection (age, parity, obstetric history), its
clinical course and subsequent progress to septic shock, and the site of GAS
isolation (blood, vaginal discharge, wound etc).
3. Additional information will be obtained from the patients in order to evaluate the
incidence of gynaecological infections and risk factors for such infections. These
include events of pelvic inflammatory disease, contraceptive methods, subsequent
deliveries or D&C (a questionnaire is attached).
4. Vaginal cultures and pharyngeal swabs will be taken from all women with previous
gynecological GAS infection/isolation participating in the study, in order to
evaluate whether carriage of GAS in the vagina occurs.
2. emm typing Since we have the original isolates from women with invasive disease (those
presenting with bacteremia) we will be able to compare the specific type isolate
obtained in consequent cultures with the original isolate. Isolates will be compared by
several known bacterial attributes such as emm type, T type, and the presence of genes
for the different exotoxins. emm typing PCR of streptococcal isolates will be performed
as previously described [11], according to the recommendations of the Division of
Bacterial and Mycotic Diseases, Streptococcus pyogenes emm sequence database
(http://www.cdc.gov/ncidod/biotech/strep/doc.htm).
3. Prospective study- In addition to the above patients, women presenting from the
beginning of the study for two years, with an isolation of GAS from the vagina (even
without overt disease), will be followed in order to evaluate the significance of such
isolates. These isolates will be collected for comparison with surveillance cultures
which will be taken in the future. Vaginal cultures and pharyngeal swabs will be taken
every 2 months during the year.
;
Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02052973 -
Efficacy of Propolis Varnish Against Oral Biofilm
|
Phase 1/Phase 2 | |
Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
Completed |
NCT00884728 -
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory
|
N/A | |
Completed |
NCT01193920 -
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
|
Phase 1/Phase 2 | |
Terminated |
NCT00261742 -
Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis
|
Phase 4 | |
Completed |
NCT00169481 -
A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine
|
Phase 2 | |
Completed |
NCT02270944 -
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
|
Phase 2 | |
Completed |
NCT03055728 -
Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
|
||
Withdrawn |
NCT00598429 -
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
|
Phase 2 | |
Completed |
NCT01030731 -
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
|
Phase 1 | |
Completed |
NCT04100772 -
Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above
|
Phase 1 | |
Completed |
NCT01118143 -
Oral Health Literacy Tailored Communication
|
N/A | |
Completed |
NCT01026740 -
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT00330642 -
Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study
|
N/A | |
Completed |
NCT00646958 -
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
|
Phase 2 | |
Completed |
NCT01026636 -
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
|
Phase 1 | |
Completed |
NCT00514527 -
A Study for Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT01026558 -
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
|
Phase 1 | |
Completed |
NCT01156740 -
Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings
|
N/A | |
Completed |
NCT04841369 -
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
|
Phase 3 |